The Reducing Inflammation For Greater Health Trial (RIGHT) Study-Concept, Rationale, And Design
As we age, our bodies can experience a low-grade, persistent inflammation, often without obvious symptoms. This chronic inflammation is thought to contribute to a decline in various aspects of health, including how well we can move, think, and even the health of our blood vessels.
Researchers are exploring whether directly addressing this age-related inflammation could lead to better health outcomes in older adults. A new study is designed to test this idea by investigating a medication called clazakizumab. This drug works by blocking a specific protein in the body called interleukin-6 (IL-6), which is a key player in inflammatory responses. By inhibiting IL-6, the medication aims to reduce the overall inflammatory burden.
The trial involves older participants and will assess if this anti-inflammatory treatment can improve their walking ability, mental sharpness, and the health of their arteries, compared to a placebo (an inactive substance). The findings from this research are expected to shed light on a significant scientific concept: whether intervening in fundamental aging processes, like inflammation, can broadly enhance health and well-being in later life.
Source: link to paper